Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

被引：5

作者：

Foti, RS ^{[1
]}

Fisher, MB ^{[1
]}

机构：

[1] Pfizer Inc, PGRD, Discovery Pharmacokinet Dynam & Metab, Groton, CT 06340 USA

来源：

PHARMACOGENOMICS JOURNAL | 2004年 / 4卷 / 06期

关键词：

D O I：

10.1038/sj.tpj.6500286

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

[No abstract available]

引用

页码：362 / 364

页数：3

共 14 条

[1] Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women [J].

Floyd, MD ;

Gervasini, G ;

Masica, AL ;

Mayo, G ;

George, AL ;

Bhat, K ;

Kim, RB ;

Wilkinson, GR .

PHARMACOGENETICS, 2003, 13 (10) :595-606

[2] CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers [J].

Fukuda T. ;

Onishi S. ;

Fukuen S. ;

Ikenaga Y. ;

Ohno M. ;

Hoshino K. ;

Matsumoto K. ;

Maihara A. ;

Momiyama K. ;

Ito T. ;

Fujio Y. ;

Azuma J. .

The Pharmacogenomics Journal, 2004, 4 (1) :34-39

[3] Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus [J].

Hesselink, DA ;

van Schaik, RHN ;

van der Heiden, IP ;

van der Werf, M ;

Gregoor, PJHS ;

Lindemans, J ;

Weimar, W ;

van Gelder, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) :245-254

[4]

Johnson Lynt B, 2004, N C Med J, V65, P35

[5] End-stage renal disease in African-American and white men - 16-year MRFIT findings [J].

Klag, MJ ;

Whelton, PK ;

Randall, BL ;

Neaton, JD ;

Brancati, FL ;

Stamler, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (16) :1293-1298

[6] Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].

Kuehl, P ;

Zhang, J ;

Lin, Y ;

Lamba, J ;

Assem, M ;

Schuetz, J ;

Watkins, PB ;

Daly, A ;

Wrighton, SA ;

Hall, SD ;

Maurel, P ;

Relling, M ;

Brimer, C ;

Yasuda, K ;

Venkataramanan, R ;

Strom, S ;

Thummel, K ;

Boguski, MS ;

Schuetz, E .

NATURE GENETICS, 2001, 27 (04) :383-391

[7] Common allelic variants of cytochrome P4503A4 and their prevalence in different populations [J].

Lamba, JK ;

Lin, YS ;

Thummel, K ;

Daly, A ;

Watkins, PB ;

Strom, S ;

Zhang, J ;

Schuetz, EG .

PHARMACOGENETICS, 2002, 12 (02) :121-132

[8] Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine [J].

Neylan, JF .

TRANSPLANTATION, 1998, 65 (04) :515-523

[9] Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes [J].

Shih, PS ;

Huang, JD .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) :1491-1496

[10] Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients [J].

Thervet, E ;

Anglicheau, D ;

King, B ;

Schlageter, MH ;

Cassinat, B ;

Beaune, P ;

Legendre, C ;

Daly, AK .

TRANSPLANTATION, 2003, 76 (08) :1233-1235

← 1 2 →